REGN - Company ID 0000872589
REGENERON PHARMACEUTICALS, INC. (REGN) reported net income of $4.50B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $4.50B | +2.1% |
| FY 2024 | $4.41B | +11.6% |
| FY 2023 | $3.95B | -8.9% |
| FY 2022 | $4.34B | -46.3% |
| FY 2021 | $8.08B | +129.9% |
| FY 2020 | $3.51B | +66.0% |
| FY 2019 | $2.12B | -13.4% |
| FY 2018 | $2.44B | +104.0% |
| FY 2017 |
REGENERON PHARMACEUTICALS, INC. (REGN) reported net income of $4.50B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, REGENERON PHARMACEUTICALS, INC.'s net income grew from -$221.76M to $4.50B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.20B |
| +33.8% |
| FY 2016 | $895.50M | +40.8% |
| FY 2015 | $636.06M | +88.1% |
| FY 2014 | $338.13M | -18.3% |
| FY 2013 | $413.74M | -44.9% |
| FY 2012 | $750.27M | +438.3% |
| FY 2011 | -$221.76M | - |